Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.55 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 7/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.47 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31233151 | 1.00 | CYSLTR1 (0.59) | CYSLTR1ABCG2CYSLTR2MAOBAPP | |
| SCHEMBL498936 | 0.86 | MAPT (0.50) | APP | |
| SCHEMBL30383422 | 0.86 | MAPT (0.50) | APP | |
| SCHEMBL499270 | 0.82 | TTR (0.48) | APP | |
| SCHEMBL498877 | 0.80 | MAPT (0.47) | CYSLTR1ABCG2MAOBAPPMAOA | |
| SCHEMBL498928 | 0.77 | CYP1A1 (0.51) | ABCG2MAOBDHODHMAOACYP1B1 | |
| SCHEMBL27747073 | 0.76 | ALDH1A1 (0.56) | — | |
| SCHEMBL13480847 | 0.76 | MAOB (0.72) | ABCG2MAOBMAOACYP1B1CXCL12 | |
| SCHEMBL25265340 | 0.74 | CYSLTR1 (1.00) | CYSLTR1ABCG2CYSLTR2MAOBAPP | |
| SCHEMBL25197758 | 0.74 | SRD5A2 (0.59) | ABCG2MAOBAPPDHODHMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058308-B2 | Substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2011-11-15 | — | — | US | claimed |
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | claimed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | claimed |
| EP-1525177-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-27 | — | — | EP | claimed |
| EP-1519908-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-06 | — | — | EP | claimed |
| WO-2004005243-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | GENFIT (FR) | 2004-01-15 | — | — | WO | claimed |
| WO-2004005233-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | GENFIT (FR) | 2004-01-15 | — | — | WO | claimed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-8461212-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2012-05-24 | — | — | US | disclosed |
| US-20050176808-A1 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | GENFIT (FR) | 2005-08-11 | — | — | US | disclosed |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2005-08-04 | — | — | US | disclosed |
| EP-1525177-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-27 | — | — | EP | disclosed |
| EP-1519908-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-06 | — | — | EP | disclosed |
| WO-2005005369-A1 | PREPARATION OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | GENFIT (FR) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004005243-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | GENFIT (FR) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004005233-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | GENFIT (FR) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | PSEN1, BACE1, PSEN2 | CYSLTR1 1861/4885ABCG2 2957/4885CYSLTR2 2097/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | CYSLTR1 3956/4885ABCG2 1606/4885CYSLTR2 3789/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | CYSLTR1 2263/4885ABCG2 3622/4885CYSLTR2 2710/4885 |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | BRCA1, COL1A1, APOL1 | CYSLTR1 1449/4885ABCG2 4139/4885CYSLTR2 2735/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | CYSLTR1 2263/4885ABCG2 3622/4885CYSLTR2 2710/4885 |
| US-20050176808-A1 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | PGF, PTGS1, PTGES3 | CYSLTR1 1821/4885ABCG2 828/4885CYSLTR2 1754/4885 |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | BRCA1, LOXL1, APOL1 | CYSLTR1 1093/4885ABCG2 3960/4885CYSLTR2 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.